[go: up one dir, main page]

WO2021074808A1 - Composition pharmaceutique comprenant du sacubitril et du valsartan et son procédé de préparation - Google Patents

Composition pharmaceutique comprenant du sacubitril et du valsartan et son procédé de préparation Download PDF

Info

Publication number
WO2021074808A1
WO2021074808A1 PCT/IB2020/059641 IB2020059641W WO2021074808A1 WO 2021074808 A1 WO2021074808 A1 WO 2021074808A1 IB 2020059641 W IB2020059641 W IB 2020059641W WO 2021074808 A1 WO2021074808 A1 WO 2021074808A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
sacubitril
copovidone
valsartan
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2020/059641
Other languages
English (en)
Inventor
Barik SATYABRATA
Parida DIPTI RANJAN
Palepu JAI KISHORE
Vishnubhotla Nagaprasad
Sivakumaran Meenakshisunderam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurobindo Pharma Ltd
Original Assignee
Aurobindo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Ltd filed Critical Aurobindo Pharma Ltd
Publication of WO2021074808A1 publication Critical patent/WO2021074808A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats

Definitions

  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising dual acting superstructures of Angiotensin receptor antagonist/blocker (ARB) and neutral endopeptidase (NEP) inhibitor, for example LCZ696.
  • ARB Angiotensin receptor antagonist/blocker
  • NEP neutral endopeptidase
  • the present invention specifically relates to a pharmaceutical composition
  • a pharmaceutical composition comprising sacubitril valsartan trisodium complex and suitable pharmaceutical excipients, process of preparation thereof and administration of such compositions for the treatment of cardiovascular diseases.
  • Cardiovascular diseases are disorders of the heart and blood vessels and include heart failure, coronary heart disease, rheumatic heart disease and other conditions. Each year 17.9 million people die from cardiovascular diseases, an estimated 31% of all deaths worldwide. Heart failure is a global pandemic affecting at least 26 million people worldwide and is increasing in prevalence. Around half of these patients with heart failure have reduced ejection fraction, which is associated with significant morbidity and mortality.
  • a dual-acting compound or combination in particular a supramolecular complex of two active agents with different mechanisms of action, or linked pro drug or in particular a supramolecular complex of two active agents with different mechanisms of action, namely an angiotensin receptor antagonist and a neutral endopeptidase inhibitor has been disclosed in U.S. Patent Application Nos. 60/735,093 filed Nov. 9, 2005; 60/735,541 filed Nov. 10, 2005; 60/789,332 filed Apr. 4, 2006; and 60/822,086 filed Aug. 11, 2006 and in International publication no. W02007/056546 which are hereby incorporated by reference in their entirety.
  • Such supramolecular complexes may be used for the treatment of patients with various cardiovascular and/or renal diseases.
  • a particularly useful therapeutic agent is the supramolecular complex, trisodium [3-((lS, 3R)-l-biphenyl-4-ylmethyl-3- ethoxycarbonyl-l-butylcarbamoyl) propionate-(S)-3'-methyl-2'-(pentanoyl ⁇ 2"- (tetrazol-5-ylate) biphenyl-4'-ylmeth-yl ⁇ amino) butyrate] hemipentahydrate also referred to as LCZ696.
  • UCZ696 a fixed dose combination
  • Sacubitril a neprilysin inhibitor
  • Valsartan an angiotensin receptor blocker. It is a salt complex comprising Sacubitril (AHU377), Valsartan, sodium cations, and water molecules in the molar ratio of 1 : 1 :3 :2.5.
  • UCZ696 dissociates into Valsartan and the pro-drug AHU377, which is further metabolized to the NEP inhibitor Sacubitrilat (LBQ657).
  • LCZ696 inhibits neprilysin via LBQ657, the active metabolite of Sacubitril, and blocks the angiotensin II type-1 receptor via Valsartan.
  • the approved dosage for fixed dose combination of Sacubitril and Valsartan is available in USA under brand name Entresto ® marketed by Novartis Pharmaceuticals.
  • Entresto is an oral film coated tablet available in three strengths viz. 50mg (24mg; 26mg), lOOmg (49mg; 51mg) and 200mg (97mg; 103mg).
  • LCZ696 which has a molecular mass of 957.99 and a molecular formula of C 48 H 55 N 6 0gNa 3 , 2.5 EhO.
  • the chemical structure of LCZ696 is:
  • US Patent 8,877,938 discloses a supramolecular complex of trisodium Sacubitril-Valsartan hemipentahydrate crystalline form.
  • US20100267786 of Novartis discloses solid oral dosage forms, especially tablets, comprising a supramolecular complex i.e. trisodium Sacubitril-Valsartan hemipentahydrate, which can be formed from a direct compression process or a compaction process such as roller compaction.
  • a supramolecular complex i.e. trisodium Sacubitril-Valsartan hemipentahydrate, which can be formed from a direct compression process or a compaction process such as roller compaction.
  • wetting agents and/or bioenhancers may not be uniformly distributed throughout the composition due to differences in particle size and mass that may lead to dissolution and bioavailability issues.
  • suitable excipients and also a best process of making the compositions to attain desired invitro release profile and/or target pharmacokinetic parameters.
  • the present invention features a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutic agent, a supramolecular complex.
  • An aspect of the present invention relates to featured supramolecular complex is a dual acting compound.
  • a dual-acting compound or combination features a supramolecular complex of two active agents with different mechanisms of action, or linked pro-drug or in particular a supramolecular complex of two active agents with different mechanisms of action, namely an angiotensin receptor antagonist and a neutral endopeptidase inhibitor.
  • An aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising trisodium [3-((lS, 3R)-l-biphenyl-4-ylmethyl-3-ethoxycarbonyl-l- butylcarbamoyl) propionate-(S)-3'-methyl-2'-(pentanoyl ⁇ 2"-(tetrazol-5-ylate) biphenyl -4'-ylmeth-yl ⁇ amino) butyrate].
  • An aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising sacubitril valsartan trisodium complex and atleast one pharmaceutically acceptable excipients selected from the group consisting of diluents, binders, disintegrants, glidants, lubricants, wetting agents and others.
  • the sacubitril valsartan trisodium complex in the pharmaceutical composition of the present invention can be either a crystalline or an amorphous form.
  • An aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising an amorphous and anhydrous solid dispersion of sacubitril valsartan trisodium complex and Copovidone.
  • An aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising amorphous sacubitril valsartan trisodium complex, Copovidone, Microcrystalline cellulose, Poloxamer, Low substituted Hydroxypropyl cellulose (L-HPC), Crospovidone, Talc, Colloidal silicon dioxide and Magnesium stearate.
  • An aspect of the present invention relates to a process for preparing the pharmaceutical composition comprising sacubitril valsartan trisodium complex and atleast one pharmaceutically acceptable excipients.
  • compositions comprising sacubitril valsartan trisodium complex and atleast one pharmaceutically acceptable excipients and use of such compositions for the treatment of cardiovascular diseases.
  • treatment includes prophylactic and/or therapeutic treatments.
  • prophylactic or therapeutic treatment is art-recognized and includes administration to the subject of one or more of the pharmaceutical compositions.
  • the treatment is prophylactic (i.e., it protects the subject against developing the unwanted condition), whereas if it is administered after manifestation of the unwanted condition, the treatment is therapeutic, (i.e., it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof).
  • cardiovascular disease(s) refers to a disorder of the heart and blood vessels, and includes disorders of the arteries, veins, arterioles, venules, and capillaries.
  • Non-limiting examples of cardiovascular diseases include cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure. Additional examples of cardiovascular diseases are known in the art.
  • One of the uses of the present invention compositions is to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
  • administering refers to a method of giving a dosage of a pharmaceutical composition to a subject.
  • the preferred method of administration may depend on a variety of factors, e.g., the components of the pharmaceutical composition or condition, and severity of the disease, disorder, or condition.
  • patient refers to a vertebrate, preferably a mammal.
  • Non-limiting examples include mice, dogs, rabbits, farm animals, sport animals, pets, and humans.
  • bioavailability can denote the degree to which a drug or other substance becomes available to the target tissue after administration.
  • pharmaceutically acceptable excipient(s) refers to those substances that are well accepted by the industry and regulatory agencies such as those listed in monographs published in compendia such as USP-NF, Food Chemicals Codex, Code of Federal Regulations (CFR), FDA Inactive Ingredients Guide and in 21 CFR parts 182 and 184 that lists substances that are generally regarded as safe (GRAS) food ingredients.
  • pharmaceutical composition refers to a pharmaceutical preparation that contains a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, and is suitable for administration to a patient for therapeutic purposes.
  • % by weight is based on the weight of the total composition.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutic agent, a supramolecular complex.
  • the present invention relates to featured supramolecular complex is a dual acting compound.
  • a dual-acting compound or combination features a supramolecular complex of two active agents with different mechanisms of action, or linked pro-drug or in particular a supramolecular complex of two active agents with different mechanisms of action, namely an angiotensin receptor antagonist and a neutral endopeptidase inhibitor.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising trisodium [3-((lS, 3R)-l-biphenyl-4-ylmethyl-3- ethoxycarbonyl-l-butylcarbamoyl) propionate-(S)-3'-methyl-2'- (pentanoyl ⁇ 2"- (tetrazol-5-ylate) biphenyl-4'-ylmeth- yl ⁇ amino) butyrate].
  • the sacubitril valsartan trisodium complex in the pharmaceutical composition of the present invention can be either a crystalline or an amorphous form.
  • the active ingredients Sacubitril and Valsartan may be present in the form of free base(s), its salt(s), polymorph(s), hydrate(s), solvate(s), conjugate(s), complex(s), prodrug(s), and derivative as alone or in combination thereof which may be present in the form of a complex, a premix, an amorphous powder, a solid dispersion, an anhydrous solid dispersion a solid solution, a physical mixture and the like.
  • the present invention provides a pharmaceutical composition comprising amorphous sacubitril valsartan trisodium complex in about 45 % by weight to about 70 % by weight of the total composition.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising sacubitril valsartan trisodium complex and atleast one pharmaceutically acceptable excipients selected from the group consisting of diluents, binders, disintegrants, glidants, lubricants, wetting agents and others.
  • the sacubitril valsartan trisodium complex in the pharmaceutical composition of the present invention can be either a crystalline or an amorphous form.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising an amorphous/anhydrous solid dispersion of sacubitril valsartan trisodium complex and atleast one pharmaceutically acceptable excipient(s).
  • the excipient used in the present invention is selected from the group of polymeric compounds like methacrylic acid copolymers, polyvinylpyrrolidone, 4-vinylpyrrolidone-vinyl acetate copolymer (copovidone), hydroxy propyl cellulose, hydroxypropylmethyl cellulose, hypromellose phthalate and the like.
  • the present invention provides copovidone, wherein the solid dispersion is prepared by dissolving sacubitril or its salt and valsartan or its salt in a suitable solvent (for eg. Ethanol), adding a base (for eg. NaoH), concentrating the solution to residue, mixing the residue with copovidone in a suitable solvent (for eg. Water) and removing the solvent. The final product is obtained by filtration followed by lyophilization.
  • the present invention provides a solid dispersion of sacubitril-valsartan complex with copovidone in a predefined weight ratio of about 1: 1:0.25 to about 1: 1:2, with optional water molecule.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising an amorphous sacubitril-valsartan trisodium with copovidone premix, which is prepared by removing the solvent from the solution containing sacubitril, valsartan, a base and copovidone in a suitable solvent.
  • diluent(s) or filler(s) examples include but not limited to cellulose derivatives, such as microcrystalline cellulose or silicified microcrystalline cellulose or wood cellulose, lactose, sucrose, starch, pregelatinized starch, dextrose, mannitol, fructose, xylitol, sorbitol, com starch, modified com starch, inorganic salts such as calcium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, dextrin/dextrates, maltodextrin, and compressible sugars.
  • diluents are added in an amount from about 10% to about 90% by weight of the total composition.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising sacubitril valsartan trisodium complex and microcrystalline cellulose as a diluent.
  • binder(s) for use in accordance with the present invention include but not limited to cellulose and its derivatives including hydroxypropylmethyl cellulose (hypromellose), hydroxypropyl cellulose, hydroxypropyl cellulose (HPC), cellulose acetate, ethylcellulose, methylcellouse, and hydroxyethyl cellulose; starch and its derivatives; pregelatinized starch, hydrocolloids; sugar; polyvinyl pyrrolidone, copovidone, methacryclic acid copolymers and combinations thereof, and the like.
  • disintegrant(s) suitable for use herein include but not limited to croscarmellose sodium, crospovidone, starch, potato starch, pregelatinized starch, com starch, sodium starch glycolate, low substituted hydroxypropyl cellulose (L- HPC) and other known disintegrant(s).
  • disintegrants in an amount from about 1% to about 15% by weight of the total composition.
  • the present invention provides a pharmaceutical composition comprising sacubitril valsartan trisodium complex and disintegrants selected from crospovidone, low substituted hydroxypropyl cellulose or mixtures thereof.
  • wetting agent(s) suitable for use herein include but not limited to poloxamer, polyoxyethylene ethers, polyoxyethylene sorbitan fatty acid esters, polyoxymethylene stearate, sodium lauryl sulfate, sorbitan fatty acid esters, benzalkonium chloride, polyethoxylated castor oil, and docusate sodium.
  • wetting agents in an amount from about 1% to about 10% by weight of the total composition.
  • the present invention provides a pharmaceutical composition comprising sacubitril valsartan trisodium complex and poloxamer as a wetting agent.
  • lubricant(s) suitable for use herein include but not limited to sodium stearyl fumarate, magnesium stearate, zinc stearate, calcium stearate, talc, camauba wax, stearic acid, palmitic acid, sodium stearyl fumarate, sodium laurel sulfate, glyceryl palmitostearate, palmitic acid, myristic acid and hydrogenated vegetable oils and fats.
  • lubricants in an amount from about 1% to about 5% by weight of the total composition.
  • the present invention provides a pharmaceutical composition comprising sacubitril valsartan trisodium complex and magnesium stearate as lubricant.
  • glidant(s) suitable for use herein include talc, colloidal silicon dioxide, silicic acid, cornstarch, calcium silicate, magnesium carbonate, magnesium oxide, magnesium silicate, starch, castor wax.
  • lubricants in an amount from about 1% to about 5% by weight of the total composition.
  • the present invention provides a pharmaceutical composition comprising sacubitril valsartan trisodium complex and colloidal silicon dioxide as glidant.
  • the present invention relates to a pharmaceutical composition comprising a solid dispersion of sacubitril valsartan trisodium complex and copovidone alongwith a wetting agent, for eg. Poloxamer.
  • composition(s) of the present invention may be provided in any pharmaceutically acceptable oral solid dosage form(s).
  • the oral solid dosage form is selected from the group consisting of tablets, mini-tablets, multilayer tablets, inlaid tablets, tablet in tablet, granules, multi-unit particulate systems (MUPS), pellets, beads, pellets presented in a sachet, capsules such as soft and hard gelatin capsules or lozenges and the like.
  • MUPS multi-unit particulate systems
  • a tablet comprising amorphous sacubitril valsartan trisodium complex, Copovidone, Microcrystalline cellulose, Low substituted Hydroxypropyl cellulose, Crospovidone, Talc, Colloidal silicon dioxide and Magnesium stearate.
  • the process of preparation of dosage forms in accordance with the embodiments are designed by considering the couple of problems of sacubitril valsartan trisodium complex, especially it is strictly ensured that there is no exposure of the therapeutic agent to moisture, no exposure of excessive heat and/or high shear forces as these possess a number of formulation incompatibilities and difficulties during the formulation process, which may lead to degradation or dissociation of the therapeutic agent and/or increased amorphism of the components of the dual acting compound selected for this invention.
  • Sacubitril -valsartan supramolecular complex is a BCS class IV compound which resembles a low solubility and low permeability.
  • formulation scientists have encountered a problem of non-uniform distribution of wetting agent, for eg. Poloxamer during granulation and/or blending the formulation development of sacubitril-valsartan supramolecular complex.
  • the inventors of the present invention have overcome the aforementioned problems and developed a novel process for preparing a pharmaceutical composition comprising amorphous sacubitril valsartan trisodium complex with copovidone comprising of: i) sifting a diluent; ii) preparing granulating fluid comprising of poloxamer and water; iii) granulating the diluent of step (i) with granulating fluid of step (ii) followed by drying; iv) blending the dried granules of step (iii) with extragranular components comprising amorphous sacubitril valsartan trisodium complex with copovidone and at least one pharmaceutically acceptable excipient; v) compressing or fdling the blend of step (iv) into an oral solid dosage form; vi) optionally coating the oral solid dosage form of step v.
  • the present invention relates to a process for preparing a pharmaceutical composition comprising amorphous sacubitril valsartan trisodium complex with copovidone comprising of: i) sifting microcrystalline cellulose; ii) preparing granulating fluid comprising poloxamer and water; iii) granulating the microcrystalline cellulose with granulating fluid of step (ii) followed by drying; iv) blending the dried granules of step (iii) with extragranular components comprising of amorphous sacubitril valsartan trisodium complex with copovidone, L-HPC, crospovidone, talc, colloidal silicon dioxide and magnesium stearate; v) compressing or fdling the blend of step (iv) into an oral solid dosage form; vi) optionally coating the oral solid dosage form of step v.
  • the inventors of the present invention have overcome the aforementioned problems and developed a novel process for preparing a pharmaceutical composition comprising Sacubitril-Valsartan complex, wherein the process comprises: i) sifting intragranular excipient(s) selected from the group consisting of diluent(s), binder(s), disintegrant(s) and lubricant(s); ii) preparing granulating fluid comprising wetting agent and water; iii) granulating the intragranular excipient(s) with granulating fluid of step (ii) in rapid mixer granulator (RMG) and drying and milling; iii) blending the milled material with extragranular components comprising Sacubitril-Valsartan complex and excipient(s) selected from the group consisting of disintegrant(s), glidant(s), and lubricant(s); iv) compacting the lubricated blend by roller compaction and milling; v
  • the present invention relates to a pharmaceutical composition comprising Sacubitril-Valsartan complex, wherein the process comprises: i) Sifting microcrystalline cellulose; ii) preparing granulating fluid comprising poloxamer and water; iii) granulating the microcrystalline cellulose with granulating fluid of step (ii) in rapid mixer granulator and drying; iv) blending the dried granules of step (iii) for 10 minutes with extragranular components comprising Solid dispersion of Sacubitril and Valsartan with Copovidone, low-substituted hydroxypropyl cellulose, crospovidone, talc, colloidal silicon dioxide and magnesium stearate; iv) slugging the blend of step (iii) in roller compactor followed by milling; v) blending the milled material with crospovidone for 10 minutes and lubricating with magnesium stearate for 3 minutes; vi) The final blend was compressed
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a solid dispersion of sacubitril valsartan trisodium complex with copovidone and a wetting agent, wherein the composition exhibits % drug release of atleast 15% to 20% of sacubitril and atleast 15% to 20% of valsartan in 0.1N HC1 at 60 minutes.
  • the tablets of the invention has an optional protective outer layer i.e. tablet coating.
  • the protective outer layer of the tablet is based on the weight of the pharmaceutical formulation.
  • the formulation can contain at least one coating layer polymer and a non-aqueous coating solvent(s), for example, isopropyl alcohol which is used for processing and removed by drying.
  • Suitable examples of polymer(s) for the coating layer include but not limited to hydroxypropyl methylcellulose, polyvinyl alcohol (PVA), ethyl cellulose, methacrylic polymers, hydroxypropyl cellulose, and starch.
  • the film coat composition comprises plasticizer(s).
  • plasticizer(s) include but not limited to glycerol monocaprylocaprate, triacetin, diethyl phthalate, tributyl sebacate, polyethylene glycol (PEG)/macrogol, glycerin, and tri ethyl citrate.
  • the film coating composition may optionally comprises ant adherent(s) or opacifying agent(s) or dye(s) or combinations thereof including but not limited to talc, aluminum lakes, iron oxides, titanium dioxide and natural colors.
  • the film coating composition comprises hypromellose, titanium dioxide, polyethylene glycol (PEG)/macrogol, talc, iron oxide black, iron oxide red and iron oxide yellow.
  • dissolution refers to a process by which a solid substance, here the active ingredients, is dispersed in molecular form in a medium.
  • the dissolution rate of the active ingredients of the pharmaceutical oral fixed dose combination of the invention is defined by the amount of drug substance that goes in solution per unit time under standardized conditions of liquid/solid interface, temperature and solvent composition.
  • the dissolution rate is measured by standard methods known to the person skilled in the art, see the harmonized procedure set forth in the pharmacopeias USP ⁇ 711> and EP 2.9.3 and JP.
  • the test is for measuring the dissolution of the individual active ingredients is performed at pH 1.2 using a paddle stirring element at 50 rpm (rotations per minute) or alternatively at 75 rpm using a paddle stirring element as specified.
  • the dissolution medium is preferably a buffer, typically a phosphate buffer or 0.1N HC1, especially one as described in the example "Dissolution Test".
  • 0.1N HC1 is considered because, it is a differentiating medium for several compositions and thereby it would be easy to predict desired in vitro release profile and/or target pharmacokinetic parameters of active ingredients.
  • the present invention provides preferably solid oral dosage forms delivering a therapeutically effective amount of valsartan free acid or a pharmaceutically acceptable salt thereof and Sacubitril free acid, or a pharmaceutically acceptable salt thereof.
  • the present invention provides preferably solid oral dosage forms exhibit an in vitro dissolution profile, when measured by the USP paddle method at about 50 rpm or at about 75 rpm in 900 mF of 0. IN HC1 at pH 1.2 and at 37 ⁇ 0.5° C., such that after 60 min, from a mean of about 10% to a mean of about 20% (by weight) of valsartan free acid, or a pharmaceutically acceptable salt thereof and Sacubitril free acid, or a pharmaceutically acceptable salt thereof, is released.
  • Amorphous Solid dispersion of Sacubitril and Valsartan with Copovidone was sifted with Microcrystalline Cellulose, Low Substituted Hydroxypropyl Cellulose, Crospovidone, Talc, Colloidal silicon dioxide and Magnesium stearate.
  • the sifted materials were blended in octagonal blender for 10 minutes.
  • the blended material was then compacted in roller compactor and milled.
  • the milled material was sifted and blended with Crospovidone and Talc for 10 minutes and lubricated with the previously sifted Magnesium stearate for 5 minutes.
  • the lubricated blend was compressed into a tablet with a suitable tablet tooling and film -coated in a pan coater.
  • Amorphous Solid dispersion of Sacubitril and Valsartan with Copovidone was co-milled.
  • the Milled complex was sifted with Polysorbate-80 and again co- sifted with Microcrystaline cellulose, Low substitued hydroxy propyl cellulose, Crospovidone, Talc and Colloidal Silicon dioxide.
  • the sifted materials were blended in octagonal blender for 20 minutes and then lubricated with the previously sifted magnesium stearate for 3 minutes.
  • the lubricated blend was compacted by roller compaction and milled.
  • the milled material was blended with Crospovidone and Talc. Magnesium stearate was added to the obtained blend and compressed into a tablet with a suitable tablet tooling and film-coated in a pan coater.
  • Amorphous Solid dispersion of Sacubitril and Valsartan with Copovidone was co-sifted with SLS, Microcrystalline Cellulose, Low Substituted Hydroxypropyl Cellulose, Crospovidone, Talc, Colloidal silicon dioxide and Magnesium stearate and blended in an octagonal blender for 10 minutes.
  • the blend was compacted by roller compactor and milled.
  • the milled material was loaded in a blender with Crospovidone and Talc and blended for 10 minutes.
  • To this blend the sifted Magnesium stearate was added for lubrication and blended for 3 minutes.
  • the lubricated blend was compressed into a tablet with a suitable tablet tooling and film- coated in a pan coater.
  • a granulating fluid comprising 25% w/w Sodium Lauryl Sulfate and water was prepared and granulated with Microcrystalline Cellulose which was drymixed already in Rapid Mixer Granulator. The wet mass was kneaded and discharged from Rapid Mixer Granulator in to Fluid Bed Equipment bowl and dried. The dried granules was sifted and co-sifted with Sacubitril-Valsartan complex, Low Substituted Hydroxypropyl Cellulose, Crospovidone, Talc and Colloidal silicon dioxide. The sifted material was blended for 10 minutes and then lubricated with Magnesium stearate and for 3 minutes. The final blend was compressed into a tablet with a suitable tablet tooling and film -coated in a pan coater.
  • a granulating fluid comprising 25% w/w Poloxamer and water was prepared and granulated with Microcrystalline Cellulose which was drymixed already in Rapid Mixer Granulator. The wet mass was kneaded and discharged from Rapid Mixer Granulator in to Fluid Bed Equipment bowl and dried. The dried granules was sifted and co-sifted with Sacubitril-Valsartan complex, Low Substituted Hydroxypropyl Cellulose, Crospovidone, Talc and Colloidal silicon dioxide. The sifted material was blended for 10 minutes and then lubricated with Magnesium stearate and for 3 minutes. The final blend was compressed into a tablet with a suitable tablet tooling and film -coated in a pan coater.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant un complexe trisodique de sacubitril-valsartan amorphe avec de la copovidone et un poloxamère et un procédé de préparation de la composition de celle-ci. La présente invention concerne également une composition pharmaceutique comprenant un complexe trisodique de sacubitril-valsartan pour le traitement de maladies cardiovasculaires telles que l'insuffisance cardiaque.
PCT/IB2020/059641 2019-10-15 2020-10-14 Composition pharmaceutique comprenant du sacubitril et du valsartan et son procédé de préparation Ceased WO2021074808A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201941041628 2019-10-15
IN201941041628 2019-10-15

Publications (1)

Publication Number Publication Date
WO2021074808A1 true WO2021074808A1 (fr) 2021-04-22

Family

ID=75538642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/059641 Ceased WO2021074808A1 (fr) 2019-10-15 2020-10-14 Composition pharmaceutique comprenant du sacubitril et du valsartan et son procédé de préparation

Country Status (1)

Country Link
WO (1) WO2021074808A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113648284A (zh) * 2021-07-16 2021-11-16 南京海纳医药科技股份有限公司 一种含有沙库巴曲缬沙坦钠的片剂及其制备方法
EP4268806A1 (fr) * 2022-04-26 2023-11-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Comprimé comprenant du sacubitril et du valsartan traité par granulation sèche

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016192680A1 (fr) * 2015-06-03 2016-12-08 Triastek, Inc. Formes galéniques et leur utilisation
WO2018069833A1 (fr) * 2016-10-10 2018-04-19 Laurus Labs Limited Forme amorphe stable d'un complexe de sacubitril-valsartan trisodique et ses procédés de préparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016192680A1 (fr) * 2015-06-03 2016-12-08 Triastek, Inc. Formes galéniques et leur utilisation
WO2018069833A1 (fr) * 2016-10-10 2018-04-19 Laurus Labs Limited Forme amorphe stable d'un complexe de sacubitril-valsartan trisodique et ses procédés de préparation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113648284A (zh) * 2021-07-16 2021-11-16 南京海纳医药科技股份有限公司 一种含有沙库巴曲缬沙坦钠的片剂及其制备方法
EP4268806A1 (fr) * 2022-04-26 2023-11-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Comprimé comprenant du sacubitril et du valsartan traité par granulation sèche

Similar Documents

Publication Publication Date Title
KR20210016436A (ko) 글루코키나제 활성화제 및 ppar 수용체 활성화제를 함유하는 약제학적 병용물, 조성물, 및 병용 제제, 및 이의 제조 방법 및 용도
KR20160101720A (ko) Azd9291을 포함하는 제약 조성물
US8758815B2 (en) Pharmaceutical compositions comprising a combination of metformin and sitagliptin
US11819577B2 (en) Fixed dose pharmaceutical composition of valsartan and sacubitril
BR112012028035B1 (pt) formulação de liberação imediata
EP2627319A1 (fr) Compositions pharmaceutiques contenant un inhibiteur dgat1
AU2019321583C1 (en) Formulations of AG10
EA021317B1 (ru) Монослойные таблетки, содержащие ирбесартан и амлодипин, их получение и их терапевтическое применение
US20200188305A1 (en) High concentration dosage forms of pridopidine
US20220409626A1 (en) Tablets for oral suspension containing rivaroxaban
US20120141586A1 (en) Thrombin receptor antagonist and clopidogrel fixed dose tablet
WO2021074808A1 (fr) Composition pharmaceutique comprenant du sacubitril et du valsartan et son procédé de préparation
RS66060B1 (sr) Sastav koji sadrži ramipril i indapamid
KR20140030505A (ko) 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
EP2701689B1 (fr) Compositions pharmaceutiques de raltégravir, procédés de préparation et utilisation de celles-ci
WO2014058047A1 (fr) Procédé de production de préparation pharmaceutique contenant un inhibiteur calcique / antagoniste du récepteur d'angiotensine ii
TWI651084B (zh) 包含異菸鹼醯胺（ｉｓｏｎｉａｚｉｄ）顆粒及利福噴丁（ｒｉｆａｐｅｎｔｉｎｅ）顆粒之包衣錠劑型態的抗肺結核穩定醫藥組合物及其製備方法
US20090263481A1 (en) Levetiracetam formulations
WO2016012898A1 (fr) Composition pharmaceutique orale de lurasidone
WO2021106004A1 (fr) Composition pharmaceutique de s-adénosylméthionine
US12285411B2 (en) Pharmaceutical composition comprising eluxadoline, process of preparation and use thereof
KR20200015758A (ko) 제약 조성물
CN108236609B (zh) 一种gpr40激动剂药物组合物及其制备方法
WO2023126973A1 (fr) Composition pharmaceutique stable d'elagolix
TW202224681A (zh) 用於治療或預防高血壓及高膽固醇血症之單一劑型的醫藥組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20877622

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20877622

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 12/09/2022)

122 Ep: pct application non-entry in european phase

Ref document number: 20877622

Country of ref document: EP

Kind code of ref document: A1